THERAPY DOSSIER · th-b03a8176757a

Injectable enzymatically crosslinked hydroxyphenyl derivative of hyaluronic acid hydrogel modified with the RGD peptide, alone or combined with fibrinogen and seeded with human Wharton jelly-derived mesenchymal stem cells

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29266693 ↗2018Mixed findings

Injectable hydroxyphenyl derivative of hyaluronic acid hydrogel modified with RGD as scaffold for spinal cord injury repair.

RatSpinal cord injuryHemisection / partialWistarMaleIntralesional injection or implantation into the spinal cord lesion cavityAcute (into the hemisection cavity) and subacute injection models

Model: Acute spinal cord hemisection and subacute spinal cord injury

Injection and implantation of the hydrogel into the acute hemisection cavity gave the same axonal and blood vessel density at 2 and 8 weeks. Subacute injection of the hydrogel with or without fibrinogen similarly promoted axonal ingrowth into the lesion, and this was further enhanced when the fibri…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…